brtxDISC (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure. ThermoStem is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
Show more
Type
Public
HQ
Melville, US
Founded
1997
Size (employees)
6 (est)
BioRestorative Therapies was founded in 1997 and is headquartered in Melville, US
Report incorrect company information

Key People/Management at BioRestorative Therapies

M.S Mark R. Weinreb

M.S Mark R. Weinreb

Chief Executive Officer, President, and Chairman
Mandy Clyde

Mandy Clyde

Vice President of Operations and Corporate Secretary
Francisco Silva

Francisco Silva

Vice President of Research and Development and Chief Scientist
Robert Paccasassi

Robert Paccasassi

Vice President, Quality and Compliance
Adam Bergstein

Adam Bergstein

Senior Vice President, Planning and Business Development

BioRestorative Therapies Office Locations

BioRestorative Therapies has an office in Melville
Melville, US (HQ)
40 Marcus Dr
Show all (1)
Report incorrect company information

BioRestorative Therapies Financials and Metrics

BioRestorative Therapies Financials

BioRestorative Therapies's revenue was reported to be $36.36 k in FY, 2016 which is a 94.2% decrease from the previous period.
USD

Revenue (Q3, 2017)

16 k

Net income (Q3, 2017)

(2.1 m)

EBIT (Q3, 2017)

(1.7 m)

Market capitalization (27-Oct-2017)

19.5 m

Closing share price (27-Oct-2017)

3.4

Cash (30-Sep-2017)

734
BioRestorative Therapies's current market capitalization is $19.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.7 k416 k628.9 k36.4 k

Revenue growth, %

24662%51%(94%)

Cost of goods sold

208 213.8 k261.5 k102

Gross profit

1.5 k202.2 k367.4 k36.3 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

125 375 175.9 k159.9 k184.9 k148.8 k96.1 k9.1 k16.2 k5 k7 k20 k16 k

Cost of goods sold

10 60 42.4 k66.1 k76.4 k74.6 k50.9 k10 71

Gross profit

115 315 133.6 k93.8 k108.5 k74.1 k45.2 k9.1 k16.1 k

Gross profit Margin, %

92%84%76%59%59%50%47%100%100%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

201.1 k91.8 k166.6 k31.8 k

Accounts Receivable

93.4 k6 k

Inventories

18 k1.9 k29.3 k

Current Assets

239.8 k114.3 k289.3 k61.7 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

642 110.4 k59.2 k374 k145.9 k6.4 k12.8 k353.1 k516.2 k6.3 k8.9 k1.9 k734

Accounts Receivable

51 k9 k16 k5 k7 k20 k16 k

Inventories

18 k17.9 k17.8 k17.4 k1.9 k2.5 k2.5 k19.6 k

Current Assets

66.3 k137.3 k95 k421.5 k180.2 k246.1 k385 k384.2 k546.2 k32.6 k38.2 k46.6 k36.3 k
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(5.6 m)(7.9 m)(8.6 m)

Depreciation and Amortization

96.7 k213.8 k258.4 k

Inventories

613 (6.8 k)

Accounts Payable

(234.6 k)1.4 m(113.2 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.3 m)(1.7 m)(1.3 m)(1.1 m)(1.8 m)(1.4 m)(1.6 m)(2.5 m)(2.3 m)(1.8 m)(2.8 m)

Inventories

17.8 k17.4 k1.9 k2.5 k2.5 k

Accounts Payable

893.4 k774.1 k1.3 m1.7 m2.1 m2.2 m2.1 m2 m2.3 m
USDY, 2017

Financial Leverage

-0.2 x
Show all financial metrics
Report incorrect company information